Speaker illustration

Doctor Taijyu Satoh

University of Pittsburgh, Pittsburgh (United States of America)

My ultimate career goal has been to become an independent scientist in the cardiovascular biology. The extensive training during my pursuit of Ph.D. degree in Tohoku University in Japan equipped me with the knowledge and skill to explore the new finding of cardiovascular pathophysiology. During my doctoral research, I focused on the pathogenesis of CTEPH. We reported that TAFI is activated in patients with CTEPH and PH model mice and rats. Importantly, TAFI-overexpressing promoted clot formation and multiple PA obstruction. After that, I started my postdoctoral research abroad at the University of Pittsburgh in 2018. Under the mentorship of Prof. Mark T. Gladwin, my basic research currently focuses on finding new mechanism of Exercise-Induced Pulmonary Hypertension (EIPH) in Heart Failure with preserved Ejection Fraction (HFpEF). We hypothesize that metabolic syndrome and oxidation of soluble guanylate cyclase β1 subunit contributes to pulmonary artery dysfunction in EIPH in HFpEF.

Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction

Event: ESC Congress 2020

Topic: Hypertension, Pulmonary Hypertension

Session: Blockbusters from the Young in Basic Science

Thumbnail

Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-

Event: ESC Congress 2017

Topic: Chronic pulmonary hypertension

Session: Young Investigator Awards Session Basic Science

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb